Constructing the fermion-boson vertex in QED3

We derive perturbative constraints on the transverse part of the fermion-boson vertex in massive QED3 through its one loop evaluation in an arbitrary covariant gauge. Written in a particular form, these constraints naturally lead us to the first non-perturbative construction of the vertex, which is in complete agreement with its one loop expansion in all momentum regimes. Without affecting its one-loop perturbative properties, we also construct an effective vertex in such a way that the unknown functions defining it have no dependence on the angle between the incoming and outgoing fermion momenta. Such a vertex should be useful for the numerical study of dynamical chiral symmetry breaking, leading to more reliable results.Comment: 13 pages, 2 figure

Electromagnetic form factors of light vector mesons

The electromagnetic form factors G_E(q^2), G_M(q^2), and G_Q(q^2), charge radii, magnetic and quadrupole moments, and decay widths of the light vector mesons rho^+, K^{*+} and K^{*0} are calculated in a Lorentz-covariant, Dyson-Schwinger equation based model using algebraic quark propagators that incorporate confinement, asymptotic freedom, and dynamical chiral symmetry breaking, and vector meson Bethe-Salpeter amplitudes closely related to the pseudoscalar amplitudes obtained from phenomenological studies of pi and K mesons. Calculated static properties of vector mesons include the charge radii and magnetic moments: r_{rho+} = 0.61 fm, r_{K*+} = 0.54 fm, and r^2_{K*0} = -0.048 fm^2; mu_{rho+} = 2.69, mu_{K*+} = 2.37, and mu_{K*0} = -0.40. The calculated static limits of the rho-meson form factors are similar to those obtained from light-front quantum mechanical calculations, but begin to differ above q^2 = 1 GeV^2 due to the dynamical evolution of the quark propagators in our approach.Comment: 8 pages of RevTeX, 5 eps figure

ONE LOOP QED VERTEX IN ANY COVARIANT GAUGE: ITS COMPLETE ANALYTIC FORM

The one loop vertex in QED is calculated in arbitrary covariant gauges as an analytic function of its momenta. The vertex is decomposed into a longitudinal part, that is fully responsible for ensuring the Ward and Ward-Takahashi identities are satisfied, and a transverse part. The transverse part is decomposed into 8 independent components each being separately free of kinematic singularities in $\bf any$ covariant gauge in a basis that modifies that proposed by Ball and Chiu. Analytic expressions for all 11 components of the ${O(\alpha)}$ vertex are given explicitly in terms of elementary functions and one Spence function. These results greatly simplify in particular kinematic regimes.Comment: 35 pages, latex, 2 figures, Complete postscript file available from: ftp://cpt1.dur.ac.uk/pub/preprints/dtp95/dtp9506/dtp9406.p

Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.

The primary objective was to compare the performance of 3 different abbreviated MRI (AMRI) sets extracted from a complete gadoxetate-enhanced MRI obtained for hepatocellular carcinoma (HCC) screening. Secondary objective was to perform a preliminary cost-effectiveness analysis, comparing each AMRI set to published ultrasound performance for HCC screening in the USA. This retrospective study included 237 consecutive patients (M/F, 146/91; mean age, 58 years) with chronic liver disease who underwent a complete gadoxetate-enhanced MRI for HCC screening in 2017 in a single institution. Two radiologists independently reviewed 3 AMRI sets extracted from the complete exam: non-contrast (NC-AMRI: T2-weighted imaging (T2wi)+diffusion-weighted imaging (DWI)), dynamic-AMRI (Dyn-AMRI: T2wi+DWI+dynamic T1wi), and hepatobiliary phase AMRI (HBP-AMRI: T2wi+DWI+T1wi during the HBP). Each patient was classified as HCC-positive/HCC-negative based on the reference standard, which consisted in all available patient data. Diagnostic performance for HCC detection was compared between sets. Estimated set characteristics, including historical ultrasound data, were incorporated into a microsimulation model for cost-effectiveness analysis. The reference standard identified 13/237 patients with HCC (prevalence, 5.5%; mean size, 33.7 ± 30 mm). Pooled sensitivities were 61.5% for NC-AMRI (95% confidence intervals, 34.4-83%), 84.6% for Dyn-AMRI (60.8-95.1%), and 80.8% for HBP-AMRI (53.6-93.9%), without difference between sets (p range, 0.06-0.16). Pooled specificities were 95.5% (92.4-97.4%), 99.8% (98.4-100%), and 94.9% (91.6-96.9%), respectively, with a significant difference between Dyn-AMRI and the other sets (p < 0.01). All AMRI methods were effective compared with ultrasound, with life-year gain of 3-12 months against incremental costs of US$ < 12,000. NC-AMRI has limited sensitivity for HCC detection, while HBP-AMRI and Dyn-AMRI showed excellent sensitivity and specificity, the latter being slightly higher for Dyn-AMRI. Cost-effectiveness estimates showed that AMRI is effective compared with ultrasound. • Comparison of different abbreviated MRI (AMRI) sets reconstructed from a complete gadoxetate MRI demonstrated that non-contrast AMRI has low sensitivity (61.5%) compared with contrast-enhanced AMRI (80.8% for hepatobiliary phase AMRI and 84.6% for dynamic AMRI), with all sets having high specificity. • Non-contrast and hepatobiliary phase AMRI can be performed in less than 14 min (including set-up time), while dynamic AMRI can be performed in less than 17 min. • All AMRI sets were cost-effective for HCC screening in at-risk population in comparison with ultrasound

State sampling dependence of the Hopfield network inference

The fully connected Hopfield network is inferred based on observed magnetizations and pairwise correlations. We present the system in the glassy phase with low temperature and high memory load. We find that the inference error is very sensitive to the form of state sampling. When a single state is sampled to compute magnetizations and correlations, the inference error is almost indistinguishable irrespective of the sampled state. However, the error can be greatly reduced if the data is collected with state transitions. Our result holds for different disorder samples and accounts for the previously observed large fluctuations of inference error at low temperatures.Comment: 4 pages, 1 figure, further discussions added and relevant references adde

Renormalization and Chiral Symmetry Breaking in Quenched QED in Arbitrary Covariant Gauge

We extend a previous Landau-gauge study of subtractive renormalization of the fermion propagator Dyson-Schwinger equation (DSE) in strong-coupling, quenched QED_4 to arbitrary covariant gauges. We use the fermion-photon proper vertex proposed by Curtis and Pennington with an additional correction term included to compensate for the small gauge-dependence induced by the ultraviolet regulator. We discuss the chiral limit and the onset of dynamical chiral symmetry breaking in the presence of nonperturbative renormalization. We extract the critical coupling in several different gauges and find evidence of a small residual gauge-dependence in this quantity.Comment: REVTEX 3.0, 27 pages including 14 Extended Postscript files comprising 9 figures. Replacement: discussion of chiral limit corrected, and some minor typographical errors fixed. To appear in Phys. Rev.

Collective perspective on advances in Dyson-Schwinger Equation QCD

We survey contemporary studies of hadrons and strongly interacting quarks using QCD's Dyson-Schwinger equations, addressing: aspects of confinement and dynamical chiral symmetry breaking; the hadron spectrum; hadron elastic and transition form factors, from small- to large-Q^2; parton distribution functions; the physics of hadrons containing one or more heavy quarks; and properties of the quark gluon plasma.Comment: 56 pages. Summary of lectures delivered by the authors at the "Workshop on AdS/CFT and Novel Approaches to Hadron and Heavy Ion Physics," 2010-10-11 to 2010-12-03, hosted by the Kavli Institute for Theoretical Physics, China, at the Chinese Academy of Science

Timing of Radiotherapy (RT) after Radical Prostatectomy (RP): Long-term outcomes in the RADICALS-RT trial [NCT00541047]

Background The optimal timing of radiotherapy (RT) after radical prostatectomy for prostate cancer has been uncertain. RADICALS-RT compared efficacy and safety of adjuvant RT versus an observation policy with salvage RT for PSA failure. Methods RADICALS-RT was a randomised controlled trial enrolling patients with ≥1 risk factor (pT3/4, Gleason 7-10, positive margins, pre-op PSA≥10ng/ml) for recurrence after radical prostatectomy. Patients were randomised 1:1 to adjuvant RT (“Adjuvant-RT”) or an observation policy with salvage RT for PSA failure (“Salvage-RT”) defined as PSA≥0.1ng/ml or 3 consecutive rises. Stratification factors were Gleason score, margin status, planned RT schedule (52.5Gy/20 fractions or 66Gy/33 fractions) and treatment centre. The primary outcome measure was freedom-from-distant metastasis, designed with 80% power to detect an improvement from 90% with Salvage-RT (control) to 95% at 10yr with Adjuvant-RT. Secondary outcome measures were bPFS, freedom-from-non-protocol hormone therapy, safety and patient-reported outcomes. Standard survival analysis methods were used; HR<1 favours Adjuvant-RT. Findings Between Oct-2007 and Dec-2016, 1396 participants from UK, Denmark, Canada and Ireland were randomised: 699 Salvage-RT, 697 Adjuvant-RT. Allocated groups were balanced with median age 65yr. 93% (649/697) Adjuvant-RT reported RT within 6m after randomisation; 39% (270/699) Salvage-RT reported RT during follow-up. Median follow-up was 7.8 years. With 80 distant metastasis events, 10yr FFDM was 93% for Adjuvant-RT and 90% for Salvage-RT: HR=0.68 (95%CI 0·43–1·07, p=0·095). Of 109 deaths, 17 were due to prostate cancer. Overall survival was not improved (HR=0.980, 95%CI 0.667–1.440, p=0.917). Adjuvant-RT reported worse urinary and faecal incontinence one year after randomisation (p=0.001); faecal incontinence remained significant after ten years (p=0.017). Interpretation Long-term results from RADICALS-RT confirm adjuvant RT after radical prostatectomy increases the risk of urinary and bowel morbidity, but does not meaningfully improve disease control. An observation policy with salvage RT for PSA failure should be the current standard after radical prostatectomy

The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019

BACKGROUND: Understanding the magnitude of cancer burden attributable to potentially modifiable risk factors is crucial for development of effective prevention and mitigation strategies. We analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 to inform cancer control planning efforts globally. METHODS: The GBD 2019 comparative risk assessment framework was used to estimate cancer burden attributable to behavioural, environmental and occupational, and metabolic risk factors. A total of 82 risk–outcome pairs were included on the basis of the World Cancer Research Fund criteria. Estimated cancer deaths and disability-adjusted life-years (DALYs) in 2019 and change in these measures between 2010 and 2019 are presented. FINDINGS: Globally, in 2019, the risk factors included in this analysis accounted for 4·45 million (95% uncertainty interval 4·01–4·94) deaths and 105 million (95·0–116) DALYs for both sexes combined, representing 44·4% (41·3–48·4) of all cancer deaths and 42·0% (39·1–45·6) of all DALYs. There were 2·88 million (2·60–3·18) risk-attributable cancer deaths in males (50·6% [47·8–54·1] of all male cancer deaths) and 1·58 million (1·36–1·84) risk-attributable cancer deaths in females (36·3% [32·5–41·3] of all female cancer deaths). The leading risk factors at the most detailed level globally for risk-attributable cancer deaths and DALYs in 2019 for both sexes combined were smoking, followed by alcohol use and high BMI. Risk-attributable cancer burden varied by world region and Socio-demographic Index (SDI), with smoking, unsafe sex, and alcohol use being the three leading risk factors for risk-attributable cancer DALYs in low SDI locations in 2019, whereas DALYs in high SDI locations mirrored the top three global risk factor rankings. From 2010 to 2019, global risk-attributable cancer deaths increased by 20·4% (12·6–28·4) and DALYs by 16·8% (8·8–25·0), with the greatest percentage increase in metabolic risks (34·7% [27·9–42·8] and 33·3% [25·8–42·0]). INTERPRETATION: The leading risk factors contributing to global cancer burden in 2019 were behavioural, whereas metabolic risk factors saw the largest increases between 2010 and 2019. Reducing exposure to these modifiable risk factors would decrease cancer mortality and DALY rates worldwide, and policies should be tailored appropriately to local cancer risk factor burden

The Cholecystectomy As A Day Case (CAAD) Score: A Validated Score of Preoperative Predictors of Successful Day-Case Cholecystectomy Using the CholeS Data Set

Background Day-case surgery is associated with significant patient and cost benefits. However, only 43% of cholecystectomy patients are discharged home the same day. One hypothesis is day-case cholecystectomy rates, defined as patients discharged the same day as their operation, may be improved by better assessment of patients using standard preoperative variables. Methods Data were extracted from a prospectively collected data set of cholecystectomy patients from 166 UK and Irish hospitals (CholeS). Cholecystectomies performed as elective procedures were divided into main (75%) and validation (25%) data sets. Preoperative predictors were identified, and a risk score of failed day case was devised using multivariate logistic regression. Receiver operating curve analysis was used to validate the score in the validation data set. Results Of the 7426 elective cholecystectomies performed, 49% of these were discharged home the same day. Same-day discharge following cholecystectomy was less likely with older patients (OR 0.18, 95% CI 0.15–0.23), higher ASA scores (OR 0.19, 95% CI 0.15–0.23), complicated cholelithiasis (OR 0.38, 95% CI 0.31 to 0.48), male gender (OR 0.66, 95% CI 0.58–0.74), previous acute gallstone-related admissions (OR 0.54, 95% CI 0.48–0.60) and preoperative endoscopic intervention (OR 0.40, 95% CI 0.34–0.47). The CAAD score was developed using these variables. When applied to the validation subgroup, a CAAD score of ≤5 was associated with 80.8% successful day-case cholecystectomy compared with 19.2% associated with a CAAD score >5 (p < 0.001). Conclusions The CAAD score which utilises data readily available from clinic letters and electronic sources can predict same-day discharges following cholecystectomy